Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. AbbVie Inc.
EIR
•AbbVie Inc.•December 15, 2021

AbbVie Inc. – FDA EIR, Dec 15, 2021

Record Details

An FDA surveillance inspection of AbbVie Inc. in North Chicago, IL, was conducted from December 8-15, 2021. This high-priority inspection, under Compliance Program 7348.810 for Sponsors and Contract Research Organizations, focused on three clinical protocols supporting a PDUFA BLA Supplemental application. The inspection comprehensively reviewed sponsor activities, including investigator selection, monitoring, quality assurance, safety reporting, and data management.

While no Form FDA 483 was issued, the inspection highlighted an issue regarding the monitoring of primary endpoint data accuracy. Specifically, numerous data entry errors for Crohn's Disease Activity Index (CDAI) scores and related components, such as data and body weight measurements, were observed across multiple clinical sites. These discrepancies were identified after the protocol-specified 12-week primary efficacy endpoint.

AbbVie's management acknowledged the findings and committed to addressing these issues through process improvements. The FDA indicated that the observed conditions would undergo further review by the agency and could potentially be considered violations of the FD&C Act, with the report forwarded to CDER for final classification.

Company
AbbVie Inc.
Inspection date
December 15, 2021
Product type
Biologics
Office
Office of Scientific Investigations
People
  • Shuhong Zhang (company_representative)
  • Yuanyuan Li (issuing_officer)
  • Erik Pulkstenis (company_representative)
  • Heather F. Bush (company_representative)
  • Ezequiel Neimark (company_representative)
View Company Profile

ID · 4ea67f2c-2701-4a6c-b4a3-6225b781f7a3

Violation Codes4
21 CFR 312.56(b)21 CFR 54.621 CFR 1121 CFR 312

Full citation text and observation details available on the Dashboard.

Other documents for AbbVie Inc.
  • 483 - 2023-01-31January 31, 2023
  • EIR - 2019-02-15February 15, 2019
  • EIR - 2018-07-02July 2, 2018
  • 483 - 2018-07-02July 2, 2018
  • EIR - 2017-12-15December 15, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore AbbVie Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.